{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:58:18Z","timestamp":1781643498285,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["OBES SURG"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intragastric balloon (IGB) therapy is a minimally invasive endoscopic intervention for weight reduction in patients with Class I-II obesity and in lower BMI patients with obesity-related comorbidities such as diabetes mellitus. Diabetes mellitus is associated with vascular complications, increased susceptibility to infection and delayed gastric emptying, underscoring the need to evaluate procedural safety and device tolerance in this population. However, evidence regarding short-term safety in this higher-risk population remains limited. This study aims to compare 30-day safety outcomes after IGB placement in patients with and without diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of 4,555 patients undergoing primary IGB placement using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database from 2015 to 2023. Propensity score-matching was performed in R version 4.5.0 to balance baseline characteristics in two matched analyses: (1) patients with diabetes mellitus matched to patients without diabetes mellitus, and (2) non-insulin dependent diabetes mellitus (NIDDM) versus insulin-dependent diabetes mellitus (IDDM). Outcomes included 30-day rates of outpatient intravenous (IV) treatments, emergency department (ED) visits, hospital readmissions, reoperations, procedural interventions, and serious adverse events (SAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with diabetes, particularly those with insulin dependence, were older, more frequently male, and had a higher burden of cardiometabolic-associated medical problems compared to patients without diabetes. Among 424 propensity-matched patients with and without diabetes, rates of 30-day healthcare utilization including outpatient IV treatment, ED visit, hospital readmission, reoperation, and procedural intervention were comparable. Postoperative SAEs were rare, with no observed significant differences in rates of organ space infection, pneumonia, unplanned intubation, pulmonary embolism, deep vein thrombosis, prolonged mechanical ventilation, urinary tract infection, renal insufficiency, acute renal failure, cerebrovascular accident, cardiac arrest, myocardial infarction, sepsis, septic shock, unplanned intensive care unit admission and mortality. In a sub-analysis of 106 matched patients with NIDDM and IDDM, 30-day healthcare utilization and all postoperative SAEs were likewise similar, with no observed statistically significant differences between cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with diabetes exhibited a greater burden of associated medical problems but demonstrated comparable rates of short-term healthcare utilization, safety outcomes and tolerability to those without diabetes after adjustment for baseline differences. These findings support the safety of IGB placement in patients with diabetes and suggest it may be considered both as a safe option for primary weight loss intervention or as a bridge therapy to Metabolic and Bariatric Surgery (MBS) in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11695-026-08622-4","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:51:14Z","timestamp":1774252274000},"page":"1849-1861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-Term Safety and Healthcare Utilization Following Intragastric Balloon Placement in Patients With and Without Diabetes Mellitus: A Propensity-Matched Analysis"],"prefix":"10.1007","volume":"36","author":[{"given":"Sevag","family":"Hamamah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil S.","family":"Samaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Samakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulmeet K.","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barham K.","family":"Abu Dayyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabindra R.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"8622_CR1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"issue":"10397","key":"8622_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"regional Global","year":"2023","unstructured":"Global regional, national burden of diabetes. from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203\u201334.","journal-title":"Lancet"},{"issue":"1","key":"8622_CR3","doi-asserted-by":"publisher","first-page":"e120124225603","DOI":"10.2174\/0115733998274323231230131843","volume":"21","author":"WC Guzman-Vilca","year":"2024","unstructured":"Guzman-Vilca WC, Carrillo-Larco RM. Number of People with Type 2 Diabetes Mellitus in 2035 and 2050: A Modelling Study in 188 Countries. Curr Diabetes Rev. 2024;21(1):e120124225603.","journal-title":"Curr Diabetes Rev"},{"key":"8622_CR4","doi-asserted-by":"publisher","first-page":"111315","DOI":"10.1016\/j.biopha.2021.111315","volume":"137","author":"B Ahmed","year":"2021","unstructured":"Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021;137:111315.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"8622_CR5","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.14309\/ajg.0000000000000239","volume":"114","author":"F Bazerbachi","year":"2019","unstructured":"Bazerbachi F, Vargas EJ, Abu Dayyeh BK. Endoscopic Bariatric Therapy: A Guide to the Intragastric Balloon. Am J Gastroenterol. 2019;114(9):1421\u201331.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"8622_CR6","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.soard.2014.12.006","volume":"11","author":"J Ponce","year":"2015","unstructured":"Ponce J, Woodman G, Swain J, Wilson E, English W, Ikramuddin S, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015;11(4):874\u201381.","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"8622_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/ijo.2016.229","volume":"41","author":"A Courcoulas","year":"2017","unstructured":"Courcoulas A, Abu Dayyeh BK, Eaton L, Robinson J, Woodman G, Fusco M, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes (Lond). 2017;41(3):427\u201333.","journal-title":"Int J Obes (Lond)"},{"key":"8622_CR8","doi-asserted-by":"crossref","unstructured":"Burgess JL, Wyant WA, Abdo Abujamra B, Kirsner RS, Jozic I. Diabetic Wound-Healing Science. Med (Kaunas). 2021;57(10).","DOI":"10.3390\/medicina57101072"},{"issue":"5","key":"8622_CR9","first-page":"442","volume":"16","author":"A Berbudi","year":"2020","unstructured":"Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. Curr Diabetes Rev. 2020;16(5):442\u20139.","journal-title":"Curr Diabetes Rev"},{"key":"8622_CR10","doi-asserted-by":"publisher","first-page":"841256","DOI":"10.3389\/fendo.2022.841256","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Hou A, Cao J, Liu Y, Lou J, Li H, et al. Association of Diabetes Mellitus With Postoperative Complications and Mortality After Non-Cardiac Surgery: A Meta-Analysis and Systematic Review. Front Endocrinol (Lausanne). 2022;13:841256.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"8622_CR11","doi-asserted-by":"publisher","first-page":"7839101","DOI":"10.1155\/2017\/7839101","volume":"2017","author":"D Huang","year":"2017","unstructured":"Huang D, Refaat M, Mohammedi K, Jayyousi A, Al Suwaidi J, Abi Khalil C. Macrovascular Complications in Patients with Diabetes and Prediabetes. Biomed Res Int. 2017;2017:7839101.","journal-title":"Biomed Res Int"},{"key":"8622_CR12","doi-asserted-by":"publisher","first-page":"117863291773507","DOI":"10.1177\/1178632917735075","volume":"10","author":"V Leung","year":"2017","unstructured":"Leung V, Ragbir-Toolsie K. Perioperative Management of Patients with Diabetes. Health Serv Insights. 2017;10:1178632917735075.","journal-title":"Health Serv Insights"},{"issue":"1","key":"8622_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11695-019-04175-x","volume":"30","author":"S Leonard-Murali","year":"2020","unstructured":"Leonard-Murali S, Nasser H, Ivanics T, Shakaroun D, Genaw J. Perioperative Outcomes of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy in Patients with Diabetes Mellitus: an Analysis of the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) Database. Obes Surg. 2020;30(1):111\u20138.","journal-title":"Obes Surg"},{"key":"8622_CR14","unstructured":"Crossan K, Sheer AJ. Intragastric Balloon. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025. StatPearls Publishing LLC.; 2025."},{"issue":"1","key":"8622_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41572-018-0038-z","volume":"4","author":"M Camilleri","year":"2018","unstructured":"Camilleri M, Chedid V, Ford AC, Haruma K, Horowitz M, Jones KL, et al. Gastroparesis Nat Rev Dis Primers. 2018;4(1):41.","journal-title":"Gastroparesis Nat Rev Dis Primers"},{"issue":"5","key":"8622_CR16","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1210\/er.2018-00161","volume":"40","author":"AE Bharucha","year":"2019","unstructured":"Bharucha AE, Kudva YC, Prichard DO. Diabetic Gastroparesis. Endocr Rev. 2019;40(5):1318\u201352.","journal-title":"Endocr Rev"},{"issue":"22","key":"8622_CR17","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1001\/jama.2014.5988","volume":"311","author":"L Sj\u00f6str\u00f6m","year":"2014","unstructured":"Sj\u00f6str\u00f6m L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden \u00c5, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297\u2013304.","journal-title":"JAMA"},{"issue":"6","key":"8622_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/a-2292-2494","volume":"56","author":"P Jirapinyo","year":"2024","unstructured":"Jirapinyo P, Hadefi A, Thompson CC, Patai \u00c1V, Pannala R, Goelder SK, et al. American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity. Endoscopy. 2024;56(6):437\u201356.","journal-title":"Endoscopy"},{"issue":"5","key":"8622_CR19","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1053\/j.gastro.2021.03.003","volume":"160","author":"T Muniraj","year":"2021","unstructured":"Muniraj T, Day LW, Teigen LM, Ho EY, Sultan S, Davitkov P, et al. AGA Clinical Practice Guidelines on Intragastric Balloons in the Management of Obesity. Gastroenterology. 2021;160(5):1799\u2013808.","journal-title":"Gastroenterology"},{"key":"8622_CR20","doi-asserted-by":"crossref","unstructured":"Khalil O, Dargham S, Jayyousi A, Al Suwaidi J, Abi Khalil C. Diabetes Is Associated with Worse Postoperative Mortality and Morbidity in Bariatric Surgery, Regardless of the Procedure. J Clin Med. 2024;13(11).","DOI":"10.3390\/jcm13113174"},{"issue":"10","key":"8622_CR21","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.soard.2019.07.026","volume":"15","author":"H Nasser","year":"2019","unstructured":"Nasser H, Ivanics T, Leonard-Murali S, Shakaroun D, Genaw J. Perioperative outcomes of laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy in super-obese and super-super-obese patients: a national database analysis. Surg Obes Relat Dis. 2019;15(10):1696\u2013703.","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"8622_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s11695-022-06437-7","volume":"33","author":"RH Shah","year":"2023","unstructured":"Shah RH, Vedantam S, Kumar S, Amin S, Pearlman M, Bhalla S. Intragastric Balloon Significantly Improves Metabolic Parameters at 6 Months: a Meta-Analysis. Obes Surg. 2023;33(3):725\u201332.","journal-title":"Obes Surg"},{"issue":"2","key":"8622_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.soard.2019.10.025","volume":"16","author":"JI Mechanick","year":"2020","unstructured":"Mechanick JI, Apovian C, Brethauer S, Garvey WT, Joffe AM, Kim J, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures\u2009\u2013\u20092019 update: cosponsored by American Association of Clinical Endocrinologists\/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020;16(2):175\u2013247.","journal-title":"Surg Obes Relat Dis"},{"issue":"5","key":"8622_CR24","doi-asserted-by":"publisher","first-page":"e204803","DOI":"10.1001\/jamanetworkopen.2020.4803","volume":"3","author":"Y Sun","year":"2020","unstructured":"Sun Y, Liu B, Smith JK, Correia MLG, Jones DL, Zhu Z, et al. Association of Preoperative Body Weight and Weight Loss With Risk of Death After Bariatric Surgery. JAMA Netw Open. 2020;3(5):e204803.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"8622_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ajg.2016.530","volume":"112","author":"VB Popov","year":"2017","unstructured":"Popov VB, Ou A, Schulman AR, Thompson CC. The Impact of Intragastric Balloons on Obesity-Related Co-Morbidities: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2017;112(3):429\u201339.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"8622_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/00365521.2021.1994641","volume":"57","author":"CJ T\u00f8nnesen","year":"2022","unstructured":"T\u00f8nnesen CJ, Hjelmes\u00e6th J, Hofs\u00f8 D, Tonstad S, Hertel JK, Heggen E, et al. A novel intragastric balloon for treatment of obesity and type 2 diabetes. A two-center pilot trial. Scand J Gastroenterol. 2022;57(2):232\u20138.","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"8622_CR27","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s11695-019-03848-x","volume":"29","author":"M Abeid","year":"2019","unstructured":"Abeid M, Kaddah T, Zaitoun NA, Alsamman MA. Efficacy and Safety of Intragastric Balloon Placements in 1600 Case, an Experience from the Middle East. Obes Surg. 2019;29(7):2087\u201391.","journal-title":"Obes Surg"},{"issue":"14","key":"8622_CR28","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"key":"8622_CR29","doi-asserted-by":"crossref","unstructured":"Watanabe JH, Kwon J, Nan B, Reikes A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc (2003). 2024;64(1):133\u2013138.","DOI":"10.1016\/j.japh.2023.10.002"},{"issue":"10","key":"8622_CR30","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","volume":"9","author":"RJ Jalleh","year":"2024","unstructured":"Jalleh RJ, Rayner CK, Hausken T, Jones KL, Camilleri M, Horowitz M. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterol Hepatol. 2024;9(10):957\u201364.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"8622_CR31","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.eprac.2022.06.006","volume":"28","author":"PB Mehta","year":"2022","unstructured":"Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence. Endocr Pract. 2022;28(9):884\u20138.","journal-title":"Endocr Pract"},{"issue":"10","key":"8622_CR32","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1053\/j.jvca.2022.06.008","volume":"36","author":"A Branco","year":"2022","unstructured":"Branco A, Fatima R, Liblik K, Jackson R, Payne D, El-Diasty M. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter-2 Inhibitors After Cardiac Surgery: A Review of Current Literature. J Cardiothorac Vasc Anesth. 2022;36(10):3877\u201386.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"8","key":"8622_CR33","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4253\/wjge.v13.i8.238","volume":"13","author":"G Stavrou","year":"2021","unstructured":"Stavrou G, Shrewsbury A, Kotzampassi K. Six intragastric balloons: Which to choose? World J Gastrointest Endosc. 2021;13(8):238\u201359.","journal-title":"World J Gastrointest Endosc"},{"issue":"1\u20132","key":"8622_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/17434440.2023.2289691","volume":"21","author":"S Ameen","year":"2024","unstructured":"Ameen S, Merchant HA. Intragastric balloons for obesity: critical review of device design, efficacy, tolerability, and unmet clinical needs. Expert Rev Med Devices. 2024;21(1\u20132):37\u201354.","journal-title":"Expert Rev Med Devices"},{"issue":"9","key":"8622_CR35","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s11695-018-3227-7","volume":"28","author":"F Bazerbachi","year":"2018","unstructured":"Bazerbachi F, Haffar S, Sawas T, Vargas EJ, Kaur RJ, Wang Z, et al. Fluid-Filled Versus Gas-Filled Intragastric Balloons as Obesity Interventions: a Network Meta-analysis of Randomized Trials. Obes Surg. 2018;28(9):2617\u201325.","journal-title":"Obes Surg"},{"issue":"6","key":"8622_CR36","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/MCG.0000000000001718","volume":"57","author":"E Swei","year":"2023","unstructured":"Swei E, Almuhaidb A, Sullivan S, Al-Shahrani A, D\u2019Souza FR, Altayar O, et al. Comparison of the Efficacy and Safety of the FDA-approved Intragastric Balloon Systems in a Clinical Setting. J Clin Gastroenterol. 2023;57(6):578\u201385.","journal-title":"J Clin Gastroenterol"},{"issue":"10315","key":"8622_CR37","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/S0140-6736(21)02394-1","volume":"398","author":"BK Abu Dayyeh","year":"2021","unstructured":"Abu Dayyeh BK, Maselli DB, Rapaka B, Lavin T, Noar M, Hussan H, et al. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet. 2021;398(10315):1965\u201373.","journal-title":"Lancet"},{"key":"8622_CR38","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/B978-0-444-53491-0.00022-5","volume":"117","author":"AI Vinik","year":"2013","unstructured":"Vinik AI, Erbas T. Diabetic autonomic neuropathy. Handb Clin Neurol. 2013;117:279\u201394.","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"8622_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/ajg.2011.310","volume":"107","author":"RS Choung","year":"2012","unstructured":"Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Melton LJ 3rd, Talley NJ. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol. 2012;107(1):82\u20138.","journal-title":"Am J Gastroenterol"}],"container-title":["Obesity Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-026-08622-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11695-026-08622-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-026-08622-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:41:27Z","timestamp":1781642487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11695-026-08622-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["8622"],"URL":"https:\/\/doi.org\/10.1007\/s11695-026-08622-4","relation":{},"ISSN":["0960-8923","1708-0428"],"issn-type":[{"value":"0960-8923","type":"print"},{"value":"1708-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilized de-identified data from the MBSAQIP database. All data were collected and provided in a manner that protects patient confidentiality, and no identifiable personal health information was accessed or used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"GPT 5.1 was used to assist with language editing during the preparation of this manuscript. The authors reviewed and approved the final content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Artificial Intelligence Disclosure"}},{"value":"Dr. Rashmi Advani is a consultant for Boston Scientific. Dr. Kulmeet K. Sandhu is a consultant for Johnson & Johnson. Dr. Kenneth Park is a consultant for Boston Scientific, Cook Medical, MicroTech, Olympus, and EndoRobotics. Dr. Barham K. Abu Dayyeh serves as a consultant for Boston Scientific and Olympus. He has received research support for the conduct of the MERIT trial from Apollo Endosurgery, now Boston Scientific; this support was provided to his previous institution (Mayo Clinic), and he did not receive personal compensation related to the trial. Dr. Barham K. Abu Dayyeh is also a co-inventor of the Endogenex technology, which has been licensed by the Mayo Clinic to Endogenex. Dr. Rabindra R. Watson is a consultant, speaker and receives research support from Boston Scientific. All other authors have no financial disclosures or conflicts of interests to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}